Open Accessibility Menu

Clinical Trial Information

Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence

Study Details

This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+

Primary Sponsor:

Departmental

Prinicipal Investigator:

Anita McSwain, MD

Contact Phone:

(202) 677-6828
Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence amchenry@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)